Donepezil (Aricept) vs GB-5001

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Alzheimer's Disease

Shared mechanism: Acetylcholinesterase · full Alzheimer's Disease pipeline

Donepezil (Aricept)

Marketed by Eisai

Approved in Alzheimer's Diseasesmall molecule
Partial signal

NCT00630851 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled 6-month study in 248 patients with severe Alzheimer's disease in Sweden. Its primary endpoint, the Severe Impairment Battery, is a validated cognitive outcome, and donepezil was statistically superior to placebo (mean difference 5.9 points). The sources read give no power calculation, so the grade is moderate.

Reported efficacy

Change from baseline in modified Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory for Severe Alzheimer's Disease (ADCS-ADL-severe) total score (Month 6); Change from baseline in Severe Impairment Battery (SIB) total score (Month 6): Primary endpoint, SIB change at 6 months: mean difference 5.9 points vs placebo, statistically significant (ARICEPT label, Swedish 6-month study, 248 randomized). (met)

Result source: NCT00630851

GB-5001

Developed by G2GBio, Inc.

Phase 1 in Alzheimer's DiseaseSmall molecule (long-acting reformulation)
Weak signal

NCT06127368 · Phase 1 · status unknown

This Phase 1 study compared a new injectable formulation with the existing oral tablet in healthy volunteers rather than in people with Alzheimer's disease. It was open-label, and it measured safety and blood drug levels rather than any effect on the disease. No serious adverse events occurred and the most common finding was mild reactions at the injection site. A study of this shape says nothing about whether the treatment helps patients.

Reported efficacy

Adverse Events (Part A: Cohort A, B : Upto Day 106 / Cohort C : Upto Day 71 / Cohort D : Upto Day 18, Part B: Cohort E, F, M : Upto Day 18 or Day 106); Clinical Laboratory tests (Part A: Cohort A, B : Upto Day 99 / Cohort C : Upto Day 64 / Cohort D : Upto Day 11, Part B: Cohort E, F, M : Upto Day 64 or Day 99); Vital Signs (Part A: Cohort A, B : Upto Day 99 / Cohort C : Upto Day 64 / Cohort D : Upto Day 11, Part B: Cohort E, F, M : Upto Day 64 or Day 99); Physical examination (Part A: Cohort A, B : Upto Day 99 / Cohort C : Upto Day 64 / Cohort D : Upto Day 11, Part B: Cohort E, F, M : Upto Day 64 or Day 99); Electrocardiograms (Part A: Cohort A, B : Upto Day 99 / Cohort C : Upto Day 64 / Cohort D : Upto Day 11, Part B: Cohort E, F, M : Upto Day 64 or Day 99): No serious adverse events were reported; the most common adverse events were mild injection site reactions, which occurred in all treatment groups except the GB-5001A IM 70 mg group and the Aricept group. (not_applicable)

Result source: NCT06127368

Results for Alzheimer's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDonepezil (Aricept)GB-5001
CDR-SB, change—Not posted · NCT00630851—Not reported
ADAS-Cog11, change—Not posted · NCT00630851—Not reported
ADCS-ADL, change—Not posted · NCT00630851—Not reported
MMSE, change—Not posted · NCT00630851—Not reported
Amyloid PET, change (centiloids)—Not posted · NCT00630851—Not reported

CDR-SB, change

Donepezil (Aricept)
—Not posted · NCT00630851
GB-5001
—Not reported

ADAS-Cog11, change

Donepezil (Aricept)
—Not posted · NCT00630851
GB-5001
—Not reported

ADCS-ADL, change

Donepezil (Aricept)
—Not posted · NCT00630851
GB-5001
—Not reported

MMSE, change

Donepezil (Aricept)
—Not posted · NCT00630851
GB-5001
—Not reported

Amyloid PET, change (centiloids)

Donepezil (Aricept)
—Not posted · NCT00630851
GB-5001
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

GB-5001: no structured comparison results are available for Alzheimer's Disease.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Donepezil (Aricept)
Primary endpoint, SIB change at 6 months: mean difference 5.9 points vs placebo, statistically significant (ARICEPT label, Swedish 6-month study, 248 randomized). NCT00630851 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Donepezil (Aricept)'s landscape · GB-5001's landscape